Study Finds RSV Antibody Shot Safe for Infants Post-Maternal Vaccination

A new study confirms that administering the antibody nirsevimab to infants post-maternal vaccination against respiratory syncytial virus is safe, enhancing protection against this common infection.

• The study reveals that infants can safely receive the antibody nirsevimab after their mothers have undergone RSV vaccination during pregnancy, providing crucial protection against respiratory syncytial virus.
• Respiratory syncytial virus is the leading cause of hospitalization for infants, highlighting the importance of effective immunization strategies to safeguard their health.
• The findings support the use of the respiratory syncytial virus vaccine in pregnant women, ensuring that their infants can benefit from enhanced antibody protection against potential infections.